Article
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Feb 2026
Pecci Federica, Agrawal Prashasti, Ross Jessica S, Ricciuti Biagio, Nakazawa Seshiru, Di Federico Alessandro, Aldea Mihaela, Garbo Edoardo, Santo Valentina, Gariazzo Eleonora, Makarem Maisam, Haradon Danielle, Odintsov Igor, Baine Marina, Travis William, Yang Soo-Ryum, Ugalde Figueroa Paula A, Gray Katherine D, Nishino Mizuki, Mayoral Penalva Maria, Jänne Pasi A, Sholl Lynette M, Awad Mark M, Chaft Jamie E
Abstract excerpt
INTRODUCTION: MET exon 14 (METex14) skipping mutations are found in 3% to 4% of NSCLC and can be detected through DNA- or RNA-based sequencing assays. Although RNA sequencing simply reports skipping of exon 14, DNA sequencing assays indicate the precise DNA nucleotide changes that result in METex14 skipping. Here, we reveal the importance of DNA-based sequencing assays for identifying patients with multiple,...
Topics
Join the communities discussing this publication.